Focusing on providing laboratory automation solutions, Xuanren Technology has completed the Series A+ strategic financing. | It is exclusively reported by 36Kr.
36Kr has learned that "XR TECHNOLOGY", a provider of high-end life science automation platforms, has recently completed a Series A+ strategic financing round. This round of financing was jointly participated by Huatai Genesee and Shunwei Capital. The raised funds will be mainly used to increase R&D investment, etc., in order to better serve cutting-edge fields such as drug research, synthetic biology, and diagnostic testing.
XR TECHNOLOGY was founded in 2020, focusing on providing products and one-stop overall solutions in the life science field (reported by 36Kr). The company's core team has accumulated rich experience in robot R&D and quality control in multinational companies; at the same time, it also has a professional biochemical team to provide customers with technical support, design delivery, and after-sales maintenance services, covering areas such as gene cells, omics analysis, molecular biology, synthetic biology, pharmaceutical R&D and production, and pharmaceutical GMP.
Image Source: XR TECHNOLOGY
The concept of laboratory automation originated in Japan in the 1980s and first appeared in the field of clinical testing. Overseas brand products are relatively mature, while the development of Chinese enterprises is relatively late. In recent years, with the rise of the domestic life science laboratory automation industry and the accelerated boost during the COVID-19 pandemic, domestic brands have gradually ushered in more development opportunities.
It is introduced that XR TECHNOLOGY's products focus on modular and standardized design capabilities. According to the different needs of customers, the company can deeply integrate robots and artificial intelligence technology into industry application scenarios to achieve rapid, stable, and efficient operations.
After years of iterative upgrades, the company has established an exquisite fluid control technology platform to ensure that liquid control and solid powder injection reach higher precision and stronger robustness. Currently, the products and solutions based on this platform technology have been fully verified in multiple industry-leading enterprises and have achieved standardized repeat purchases and deliveries in recent years.
Take the company's XR Fluent A25 liquid handling workstation as an example: The pipetting processing scenario is one of the most demanded and standardized single-item types in life science laboratories. Relevant research data claims that the global pipette market is expected to reach 1.7 billion US dollars by 2029. XR TECHNOLOGY's liquid handling workstation can achieve flexible and independent 8 channels, each channel can pipette unequal volumes, and independent Z-axis movement, etc., easily performing pipetting operations on experimental vessels such as tubes, microplates, and deep well plates. Currently, it can be applied in multiple fields such as PCR/qPCR, protein purification, and NGS.
It is also learned that XR TECHNOLOGY has established R&D and engineering centers in Shanghai, Suzhou, Wuxi, and other places.
In terms of commercialization, based on the existing standardized technology platform, XR TECHNOLOGY has successfully collaborated with customers in the fields of chemical and new energy laboratory automation, and delivered many projects. The company currently has more than 100 partners.
【Introduction of Investors】
About Genesee
Genesee Biotech Corporation Limited (HK.1548) is a global leading life science R&D and production service provider. Rooted in solid DNA synthesis technology, Genesee has now established four main business units: Life Science Services and Product Business Unit, Biologics Contract Development and Manufacturing (CDMO) Business Unit, Industrial Synthetic Product Business Unit, and Comprehensive Global Cell Therapy Company. Since its establishment in 2002, Genesee has been working with partners to accelerate scientific discoveries and therapeutic breakthroughs. Its business operations cover more than 100 countries and regions worldwide, providing high-quality services and products to more than 200,000 customers. Genesee has more than 7,200 employees worldwide. As of June 30, 2024, more than 100,000 peer-reviewed academic journal articles worldwide have cited Genesee's services and products. Adhering to the corporate mission of "Making people and nature healthier with biotechnology", Genesee is committed to becoming the "Most Trusted Biotech Company" in the world.
About Huatai Zijin
Huatai Zijin is a wholly-owned subsidiary of Huatai Securities (601688.SH) engaged in private equity investment business. Relying on the full-service chain advantage of Huatai Securities, adhering to the investment concept of "Growing together with entrepreneurs", and with rich financial and industrial resources, it provides comprehensive capital services to partners. The company has a registered capital of 6 billion yuan and a management scale of over 60 billion yuan. It has multiple funds including PE, M&A, FOF, and industry funds. Huatai Zijin adheres to industry positioning, based on solid industry research, and deeply cultivates strategic emerging industries such as medical health, TMT, and advanced manufacturing, accumulating rich industry experience and resources. Huatai Zijin's investment portfolio in the medical health industry includes: Mindray Medical (300760), WuXi AppTec (603259.SH/2359.HK), Rongchang Biologics (09995.HK), Getein Biotech (688387), BrightGene Bio-Medical Technology (688166), Aidea Pharma (688488), Bioperfectus Technologies (688399), Shandong Sino-Med Pharmacy Chain Co., Ltd. (301017), Shanghai Pumen Technology Co., Ltd. (688389), MicroPort CardioFlow Medtech Corporation (2160.HK), Vazyme Biotech Co., Ltd. (688105), Geneseeq, Acebright, Cypher Biomedical Technology, Xinqit Therapeutics, etc.
About Shunwei Capital
Shunwei Capital was founded in 2011 by Mr. Lei Jun and Mr. Tuck Lye Koh. Currently, it manages over 6 billion US dollars in US dollar and RMB dual-currency funds. The investors mainly come from global top investment institutions such as sovereign funds, family funds, Fund of Funds, and university foundations. Shunwei Capital focuses on areas such as mobile Internet, Internet +, smart hardware, intelligent manufacturing, deep technology, consumption, enterprise services, and electric vehicle ecology. Representative investment projects at home and abroad include more than 600 outstanding enterprises such as Xiaomi Group, Ninebot, Agora, iQIYI, NIO, ShareChat, Meesho, etc. It hopes to make our lives better by investing in early to growth-stage enterprises with dreams.